아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - milrinone - tablets - 5 milligram

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - milrinone - 7.5 milligram

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

sanofi-synthelabo ireland ltd - milrinone - tablets - 10 milligram

인도 - 영어 - Central Drugs Standard Control Organization

samarth - milrinone - inj - 10mg/10ml - amp.

인도 - 영어 - Central Drugs Standard Control Organization

gland ph. - milrinone - inj - 10mg/10ml - 10ml amp.

인도 - 영어 - Central Drugs Standard Control Organization

united bio. - milrinone - inj - 10mg/10ml - 1

인도 - 영어 - Central Drugs Standard Control Organization

vhb - milrinone - inj - 1mg - 1

인도 - 영어 - Central Drugs Standard Control Organization

sanofi aventis - milrinone - amp - 1mg/ml - 10ml

싱가포르 - 영어 - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - anagrelide (as hcl) - capsule - 0.61mg - anagrelide (as hcl) 0.61mg

유럽 연합 - 영어 - EMA (European Medicines Agency)

mylan pharmaceuticals limited - anagrelide hydrochloride - thrombocythemia, essential - antineoplastic agents - anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (et) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.an at-risk patientan at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.